LM Economic Consortium
  • Certified Programs
  • For Employers
  • For Healthcare Providers
Menu
  • About
  •    The Why of the
       LMERC
  •    Who
  •    Advisory Board
  •    Staff
  • Benefits
  •    For Employers
  •    For Healthcare
       Providers
  •    For Individuals
  • Resources
    • Key Papers and Presentations
    • Certified Programs
Consulting Evidence Database Download Database
Home » Evidences » Cost of Chronic Disease » Pharmaceutical cost and multimorbidity with type 2 diabetes mellitus using electronic health record data.

Pharmaceutical cost and multimorbidity with type 2 diabetes mellitus using electronic health record data.

Submitted by admin on Tue, 08/21/2018 - 17:39

Author(s):

Sancho-Mestre, C., et al.

Year Published:

2016

Journal:

BMC Health Services Research

Categories:

Cost of Chronic Disease , Cardiovascular disease , Diabetes

Link to Abstract Summary:

https://www.ncbi.nlm.nih.gov/pubmed/27534391

Link to Full Article Free Online:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989292/

Abstract:

BACKGROUND: The objective of the study is to estimate the frequency of multimorbidity in type 2 diabetes patients classified by health statuses in a European region and to determine the impact on pharmaceutical expenditure. METHODS: Cross-sectional study of the inhabitants of a southeastern European region with a population of 5,150,054, using data extracted from Electronic Health Records for 2012. 491,854 diabetic individuals were identified and selected through clinical codes, Clinical Risk Groups and diabetes treatment and/or blood glucose reagent strips. Patients with type 1 diabetes and gestational diabetes were excluded. All measurements were obtained at individual level. The prevalence of common chronic diseases and co-occurrence of diseases was established using factorial analysis. RESULTS: The estimated prevalence of diabetes was 9.6 %, with nearly 70 % of diabetic patients suffering from more than two comorbidities. The most frequent of these was hypertension, which for the groups of patients in Clinical Risk Groups (CRG) 6 and 7 was 84.3 % and 97.1 % respectively. Regarding age, elderly patients have more probability of suffering complications than younger people. Moreover, women suffer complications more frequently than men, except for retinopathy, which is more common in males. The highest use of insulins, oral antidiabetics (OAD) and combinations was found in diabetic patients who also suffered cardiovascular disease and neoplasms. The average cost for insulin was 153euro and that of OADs 306euro. Regarding total pharmaceutical cost, the greatest consumers were patients with comorbidities of respiratory illness and neoplasms, with respective average costs of 2,034.2euro and 1,886.9euro. CONCLUSIONS: Diabetes is characterized by the co-occurrence of other diseases, which has implications for disease management and leads to a considerable increase in consumption of medicines for this pathology and, as such, pharmaceutical expenditure.

Need the password to download the full database of studies?

Join our mailing list to get access to this as well as other key resources demonstrating the financial benefits of lifestyle medicine and health improvements:

Employers/Professionals Click Here

Healthcare Providers Click Here

Search and Filter

Press crtl for multiple selections
Range Between Start Year and End Year

We can help to reverse the trend, with the savings going right to your bottom line.

The solvency of our nation is at stake.

Benefits Evidence Database Consulting Resources Contact

Lifestyle Medicine Economic Research Council

The LMERC is a special project of the American College of Lifestyle Medicine, a 501(c)3 non-profit charitable organization dedicated to advancing the field of lifestyle medicine as the foundation of a transformed and sustainable system of healthcare delivery.

facebook Twitter Contact
LM Economic Consortium
© 2019 American College of Lifestyle Medicine. Site by The Nyberg Group